The agency is now reviewing the petition and a final decision could come in early 2016.
Photo © iStockphoto.com/ travellinglight
Numerous studies back the ability of Hi-Maize, a brand of digestion-resistant starch, to help minimize blood sugar spikes and aid insulin function. Now, Hi-Maize’s supplier Ingredion Inc. (Westchester, IL) is seeking an FDA health claim linking this resistant starch from high-amylose corn with reduced risk of developing type 2 diabetes.
The company reports that FDA accepted its health claim petition in July. After undergoing a comment period, the agency is now reviewing the petition and a final decision could come in early 2016.
Ingredion points out that more than 70 human clinical trials have been conducted on high-amylose resistant starch, including studies both independent and funded by the company itself. At least eight well-controlled studies show that Hi-maize “improved insulin sensitivity or other biomarkers accepted by the FDA as evidence for reduced risk of type 2 diabetes,” the company says.
“We believe that there is consistent scientific evidence showing a clear link between consumption of resistant starch from high-amylose corn and reduction of risk for type 2 diabetes,” said Christine Pelkman, PhD, senior nutrition scientist and clinical research manager, Ingredion, in a press release. She added that the outside scientific and regulatory consultants the company collaborated with agreed that the scientific portfolio behind the ingredient is strong and “that these findings provide a strong basis for a health claim petition.”
Also read:
Who Is the Blood Sugar-Management Dietary Supplement Customer?
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine
jennifer.grebow@ubm.com
FDA revokes authorization to use Red No. 3 as a color additive in food or drugs
January 15th 2025FDA contends that the color additive is safe for humans but is legally obligated by the Delaney Clause of the FD&C act to revoke authorization as research shows the Red No. 3 induces cancer in rats.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.